deltatrials
Terminated PHASE2 INTERVENTIONAL 2-arm NCT03693625

A Study to Evaluate the Long-term Safety and Efficacy of Fenebrutinib in Participants Previously Enrolled in a Fenebrutinib Chronic Spontaneous Urticaria (CSU) Study

A Phase II Open-Label Extension Study To Evaluate The Long-Term Safety And Efficacy Of Fenebrutinib In Patients Previously Enrolled In A Fenebrutinib Chronic Spontaneous Urticaria Study

Sponsor: Genentech, Inc.

Conditions Urticaria
Interventions GDC-0853
Updated 17 times since 2018 Last updated: Sep 2, 2020 Started: Sep 27, 2018 Primary completion: Oct 23, 2019 Completion: Oct 23, 2019
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

Recruitment was stopped after an interim analysis of the parent GS39684 study.

Other terminated trials from Genentech, Inc.

More terminations from Genentech, Inc.

A PHASE2 clinical study on Urticaria, this trial is terminated or withdrawn. The trial is conducted by Genentech, Inc. and has accumulated 17 data snapshots since 2018. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

~Nov 2018 – ~Jan 2019 · 2 months · monthly snapshot~Jan 2019 – ~Feb 2019 · 31 days · monthly snapshot~Feb 2019 – ~Mar 2019 · 28 days · monthly snapshot~Mar 2019 – ~May 2019 · 2 months · monthly snapshot~May 2019 – ~Jun 2019 · 31 days · monthly snapshot~Jun 2019 – ~Jul 2019 · 30 days · monthly snapshot~Jul 2019 – ~Aug 2019 · 31 days · monthly snapshot~Aug 2019 – ~Dec 2019 · 4 months · monthly snapshot~Dec 2019 – ~Jan 2020 · 31 days · monthly snapshot~Jan 2020 – ~Mar 2020 · 2 months · monthly snapshot~Mar 2020 – ~Apr 2020 · 31 days · monthly snapshot~Apr 2020 – ~Oct 2020 · 6 months · monthly snapshot~Oct 2020 – ~Jan 2021 · 3 months · monthly snapshot~Jan 2021 – ~Dec 2021 · 11 months · monthly snapshot~Dec 2021 – ~Jul 2024 · 31 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – present · 22 months · monthly snapshot

Change History

17 versions recorded

  1. Sep 2024 — Present [monthly]

    Terminated PHASE2

  2. Jul 2024 — Sep 2024 [monthly]

    Terminated PHASE2

  3. Dec 2021 — Jul 2024 [monthly]

    Terminated PHASE2

  4. Jan 2021 — Dec 2021 [monthly]

    Terminated PHASE2

  5. Oct 2020 — Jan 2021 [monthly]

    Terminated PHASE2

    Status: Completed → Terminated

▶ Show 12 earlier versions

  1. Apr 2020 — Oct 2020 [monthly]

    Completed PHASE2

  2. Mar 2020 — Apr 2020 [monthly]

    Completed PHASE2

    Status: Terminated → Completed

  3. Jan 2020 — Mar 2020 [monthly]

    Terminated PHASE2

  4. Dec 2019 — Jan 2020 [monthly]

    Terminated PHASE2

    Status: Recruiting → Terminated

  5. Aug 2019 — Dec 2019 [monthly]

    Recruiting PHASE2

  6. Jul 2019 — Aug 2019 [monthly]

    Recruiting PHASE2

  7. Jun 2019 — Jul 2019 [monthly]

    Recruiting PHASE2

  8. May 2019 — Jun 2019 [monthly]

    Recruiting PHASE2

  9. Mar 2019 — May 2019 [monthly]

    Recruiting PHASE2

  10. Feb 2019 — Mar 2019 [monthly]

    Recruiting PHASE2

  11. Jan 2019 — Feb 2019 [monthly]

    Recruiting PHASE2

    Status: Not Yet Recruiting → Recruiting

  12. Nov 2018 — Jan 2019 [monthly]

    Not Yet Recruiting PHASE2

    First recorded

Sep 2018

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Genentech, Inc.
Data source: Genentech, Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations